In vitro activity of ivermectin against Staphylococcus aureus clinical isolates.

Background: Ivermectin is an endectocide against many parasites. Though being a macrocyclic lactone, its activity against bacteria has been less known, possibly due to the fact that micromolar concentrations at tissue levels are required to achieve a therapeutic effect. Among pathogenic bacteria of major medical significance, Staphylococcus aureus cause a number of diseases in a wide variety of hosts including humans and animals. It has been attributed as one of the most pathogenic organisms. The emergence of methicillin resistance has made the treatment of S. aureus even more difficult as it is now resistant to most of the available antibiotics. Thus, search for alternate anti-staphylococcal agents requires immediate attention. Methods: Twenty-one clinical isolates of S. aureus were isolated from bovine milk collected from Lahore and Faisalabad Pakistan. Different anthelmintics including levamisole, albendazole and ivermectin were tested against S. aureus to determine their minimum inhibitory concentrations. This was followed-up by growth curve analysis, spot assay and time-kill kinetics. Results: The results showed that ivermectin but not levamisole or albendazole exhibited a potent anti-staphylococcal activity at the concentrations of 6.25 and 12.5 µg/ml against two isolates. Interestingly, one of the isolate was sensitive while the other was resistant to methicillin/cefoxitin. Conclusions: Our novel findings indicate that ivermectin has an anti-bacterial effect against certain S. aureus isolates. However, to comprehend why ivermectin did not inhibit the growth of all Staphylococci needs further investigation. Nevertheless, we have extended the broad range of known pharmacological effects of ivermectin. As pharmacology and toxicology of ivermectin are well known, its further development as an anti-staphylococcal agent is potentially appealing.

Design of all-solid leakage channel fibers with large mode area and low bending loss.

We investigate a novel design for all-solid large mode area (LMA) leakage channel fibers (LCFs) for high-power Yb-doped fiber lasers and amplifiers, based on a single down-doped-silica rod ring surrounding a seven-cell pure-silica core, aiming for effectively single-mode behavior and low bending loss characteristics. Through detailed numerical simulations based on the finite element method (FEM), we find that the proposed all-solid LMA-LCFs, having a seven-cell core and two different sizes of down-doped rods, can achieve sufficient differential mode loss and much lower bending loss, as compared with a previously-reported LCF with a one-cell core and six large down-doped-silica rods.